<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773355</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4210</org_study_id>
    <secondary_id>U1111-1170-6497</secondary_id>
    <nct_id>NCT02773355</nct_id>
  </id_info>
  <brief_title>Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients</brief_title>
  <official_title>Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in North America. The aim is to investigate timely detection of
      pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions
      possibly or probably related to Saxenda® in Mexican patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Anticipated">May 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of pancreatitis</measure>
    <time_frame>Year 0-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions (ADR)</measure>
    <time_frame>Year 0-3</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saxenda®</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide 3.0 mg</intervention_name>
    <description>Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.</description>
    <arm_group_label>Saxenda®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The medical condition investigated in this study is obesity and overweight with one or more
        weight related comorbidities. The study will aim at observing all patients exposed to
        Saxenda® during treatment by the 20 participating physicians in Mexico.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent obtained before any study-related activities (study-related activities
             are any procedure related to recording of data according to the protocol)

          -  The decision to initiate treatment with commercially available Saxenda® has been made
             by the patient/Legally Acceptable Representative (LAR) and the treating physician
             before and independently from the decision to include the patient in this study

          -  Obese patients (BMI equal to or above 30 kg/m^2) or overweight patients (BMI Equal to
             or above 27 kg/m^2) with at least one weight related comorbidity according to Saxenda®
             label text in Mexico

          -  Age equal or above 18 years at the time of signing informed consent

        Exclusion Criteria:

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation

          -  Hypersensitivity to Saxenda® or to any of its excipients

          -  Females of child-bearing potential who are pregnant, breast-feeding or intend to
             become pregnant or are not using adequate contraceptive methods (adequate
             contraceptive measures as required by local law or practice)

          -  Diagnosis of type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>Estado De México</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>66220</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Puebla</city>
        <zip>72190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

